3.3) By 2030, end the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases and combat hepatitis, water-borne diseases and other communicable diseases
As a major employer and investor in many malaria-endemic countries, ExxonMobil has witnessed the devastation of malaria firsthand. That’s why they are part of an international effort to prevent, treat and cure this deadly disease. Between 2000 and 2017, ExxonMobil has committed $163 million in cash grants to the cause, making them the largest private-sector grant-maker in the fight against malaria. ExxonMobil’s support has enabled their partners to:
- Reach more than 125 million people throughout Africa and Asia with 14.3 million bed nets, 4.3 million doses of antimalarial drugs and nearly 3 million rapid diagnostic kits
- Train 590,000 health care workers and counselors to help prevent, diagnose and treat malaria
- Hold more than 2.5 million community health sessions
- Provide technical assistance that leveraged $791 million in grants to Angola and Nigeria from the Global Fund – of which $218 million was dedicated specifically for malaria projects
- Support novel approaches to monitor resistance of current frontline antimalarial therapies and provide funding for the research and discovery of new treatments.
Since 2000, global efforts to control and eliminate malaria have brought down malaria mortality rates by 62 percent worldwide and by 69 percent in children under five years old. Through the combined power of institutions, individuals, and the communities they represent, more people are receiving prevention and treatment tools than ever before. ExxonMobil is proud to do its part in driving and maintaining these recent successes in the fight against malaria. However, much work remains to sustain momentum toward the ultimate goal of ending malaria for good.